Shire plc

Shire plc
Name	Shire plc
Type	Public limited company (formerly)
Industry	Pharmaceuticals
Founded	1986
Founders	Sir Royle Patterson, Nicholas Jonah
Fate	Acquired by Takeda Pharmaceutical Company Limited in 2019
Headquarters	Basingstoke, England; Dublin, Ireland (former)
Key people	Flemming Ornskov, Angus Russell, Matthew Emmens
Products	Vyvanse, Lialda, Firazyr, Cinryze, Adderall XR (licensed)
Revenue	£6.3 billion (2017)
Employees	~21,000 (2018)

Shire plc Shire plc was a multinational specialty biopharmaceutical company focused on rare diseases, neuroscience, and specialty conditions. Headquartered in Basingstoke and formerly in Dublin, Shire pursued growth through acquisitions, licensing, and internal development, culminating in acquisition by Takeda Pharmaceutical Company Limited in 2019. The company interacted extensively with entities such as Bain Capital, Warburg Pincus, JPMorgan Chase, Goldman Sachs, and regulators including the European Medicines Agency and the U.S. Food and Drug Administration.

History

Shire was founded in 1986 and expanded through strategic purchases including Baxalta-like deals and transactions mirroring activity by Allergan, Pfizer, GlaxoSmithKline, Novartis, and Roche. In the 1990s and 2000s Shire executed mergers and acquisitions similar to those by Valeant Pharmaceuticals International and Eli Lilly and Company, acquiring businesses with portfolios resembling Banner Health acquisitions. Key transactions involved companies such as Movetis, NPS Pharmaceuticals, ViroPharma, Advanced Medical Optics-style deals, and purchases that reshaped its pipeline comparable to moves by Amgen and Biogen Idec. Leadership under executives including Angus Russell, Flemming Ornskov, and Matthew Emmens guided global expansion into markets served by Novartis and Sanofi. The takeover by Takeda Pharmaceutical Company Limited followed bidding and regulatory reviews akin to those for Allergan acquisition offers, and closed amid scrutiny from bodies like the UK Competition and Markets Authority and the U.S. Department of Justice.

Corporate structure and ownership

Shire operated regional divisions across North America, Europe, Asia-Pacific, and Latin America with management practices resembling GlaxoSmithKline and AstraZeneca. Major shareholders included institutional investors such as BlackRock, Vanguard Group, Fidelity Investments, and private equity firms comparable to CVC Capital Partners and TPG Capital. Financial advisors on transactions included Morgan Stanley, Goldman Sachs, Credit Suisse, and Lazard. Following the acquisition, integration teams coordinated with Takeda board members and stakeholders including representatives from Irish Revenue Commissioners and corporate registries akin to Companies House. Board governance referenced precedents from firms like Bayer AG and Johnson & Johnson in committee structure and remuneration policies.

Products and therapeutic areas

Shire’s marketed medicines targeted rare genetic disorders, hematology, immunology, and central nervous system conditions, alongside gastroenterology and ophthalmology portfolios similar to offerings by Alexion Pharmaceuticals, Sobi, BioMarin Pharmaceutical, Genzyme, and Shionogi. Notable products included treatments comparable to Adderall XR for attention-deficit hyperactivity disorder alongside branded agents like Vyvanse and gastroenterology therapies similar to Lialda. Enzyme replacement and complement therapies were analogous to products from Takeda and Sanofi Genzyme. The company’s portfolio addressed conditions treated by centers such as Mayo Clinic, Cleveland Clinic, and institutions like Great Ormond Street Hospital for pediatric rare diseases.

Research and development

R&D programs combined in-house discovery with collaborations reminiscent of partnerships between Roche and Genentech, or Pfizer and BioNTech. Shire invested in clinical trials across phases I–III conducted at research hubs such as Johns Hopkins Hospital, Massachusetts General Hospital, University College London Hospitals NHS Foundation Trust, and contract research organizations like IQVIA and PPD. The company engaged in licensing deals similar to arrangements with Gilead Sciences and Regeneron Pharmaceuticals, and pursued biologics and small molecules with methods used by Amgen and Novo Nordisk. Regulatory filings were submitted to agencies including the MHRA, Health Canada, and the China National Medical Products Administration.

Financial performance

Shire reported revenues driven by specialty pharmaceuticals, with financial trajectories akin to peers Alexion, Biogen, and Celgene. Capital markets activity involved equity offerings and debt financing coordinated by Barclays, Deutsche Bank, and HSBC. Key metrics such as EBITDA and operating margin were analyzed by analysts at Morningstar, Moody's Investors Service, Standard & Poor's, and Goldman Sachs. The acquisition by Takeda was financed through a combination of cash and debt instruments underwritten by global banks including Bank of America and Deutsche Bank and required approvals similar to precedent M&A transactions overseen by the Federal Trade Commission.

Controversies and legal issues

Shire faced litigation and regulatory scrutiny over marketing practices and patent disputes comparable to cases involving Johnson & Johnson, Eli Lilly, and Merck & Co.. The company dealt with pricing debates echoing controversies around Mylan and Turing Pharmaceuticals and engaged in settlements with plaintiffs like those in actions against Valeant-type pricing strategies. Intellectual property disputes referenced disputes similar to those between Novartis and Sun Pharmaceutical Industries. Compliance reviews involved interactions with enforcement agencies including the U.S. Department of Justice, the Securities and Exchange Commission, and national health technology assessment bodies such as the National Institute for Health and Care Excellence. Post-acquisition integration also prompted scrutiny over workforce redundancies and competition concerns paralleling reviews in the European Union merger control regime.

Category:Pharmaceutical companies